Perspective Therapeutics Reports Clinical Trial Data and Hosts Conference Call

On October 23, 2026, Perspective Therapeutics, Inc. reported clinical trial data showing that 50% of patients in Cohort 3 of its radiopharmaceutical study experienced an initial response, with a disease control rate of 95%. The company reported no dose-limiting toxicities or severe treatment-emergent adverse events. A conference call was held to discuss these findings, which were previously presented at the ESMO Congress 2026, with additional data expected at medical symposia in November 2026.